Furthermore our analysis of various hematologic malignancies confirmed the significant prevalence of JAK2 mutation in AML, ALL, CML patients, contradictory to other studies that suggests JAK2 V617F is less common in leukemic patients. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.